BACKGROUND: Although warfarin therapy reduces stroke incidence in patients with atrial fibrillation (AF), the rate of warfarin use in this population remains low. In 2008, the Medicare Part D program was expanded to pay for medications for Medicare enrollees. OBJECTIVE: To examine rates and predictors of warfarin use in Medicare Part D beneficiaries with AF. METHODS: This population-based retrospective cohort study used claims data from 41,447 Medicare beneficiaries aged 66 and older with at least 2 AF diagnoses in 2007 and at least 1 diagnosis in 2008. All subjects had continuous Medicare Part D prescription coverage in 2008. Statistical analysis using χ(2) was used to examine differences in warfarin use by patient characteristics (age, ethnicity, sex, Medicaid eligibility, comorbidities, contraindications to warfarin, and whether they visited a cardiologist or a primary care physician [PCP]), CHADS(2) score (congestive heart failure, hypertension, age, diabetes, and stroke or transient ischemic attack; higher scores indicate higher risks of stroke), and geographic regions. Using hierarchical generalized linear models restricted to subjects without warfarin contraindications (n = 34,947), we examined the effect of patient characteristics and geographic regions on warfarin use. RESULTS: The overall warfarin use rate was 66.8%. The warfarin use rates varied between hospital referral regions, with highest rates in the Midwestern states and lowest rates in the South. The regional variation persisted even after adjustment for patient characteristics. Multivariable analysis showed that the odds of being on warfarin decreased significantly with age and increasing comorbidity, in blacks, and among those with low income. Seeing a cardiologist (OR 1.10; 95% CI 1.05-1.16), having a PCP (OR 1.23; 95% CI 1.17-1.29), and CHADS(2) score of 2 or greater (OR 1.09; 95% CI 1.01-1.17) were associated with increased odds of warfarin use. CONCLUSIONS: Warfarin use rates vary by patient characteristics and region, with higher rates among residents of the Midwest and among patients seen by cardiologists and PCPs. Preventing stroke-related disability in AF requires implementation of evidence-based initiatives to increase warfarin use.
BACKGROUND: Although warfarin therapy reduces stroke incidence in patients with atrial fibrillation (AF), the rate of warfarin use in this population remains low. In 2008, the Medicare Part D program was expanded to pay for medications for Medicare enrollees. OBJECTIVE: To examine rates and predictors of warfarin use in Medicare Part D beneficiaries with AF. METHODS: This population-based retrospective cohort study used claims data from 41,447 Medicare beneficiaries aged 66 and older with at least 2 AF diagnoses in 2007 and at least 1 diagnosis in 2008. All subjects had continuous Medicare Part D prescription coverage in 2008. Statistical analysis using χ(2) was used to examine differences in warfarin use by patient characteristics (age, ethnicity, sex, Medicaid eligibility, comorbidities, contraindications to warfarin, and whether they visited a cardiologist or a primary care physician [PCP]), CHADS(2) score (congestive heart failure, hypertension, age, diabetes, and stroke or transient ischemic attack; higher scores indicate higher risks of stroke), and geographic regions. Using hierarchical generalized linear models restricted to subjects without warfarin contraindications (n = 34,947), we examined the effect of patient characteristics and geographic regions on warfarin use. RESULTS: The overall warfarin use rate was 66.8%. The warfarin use rates varied between hospital referral regions, with highest rates in the Midwestern states and lowest rates in the South. The regional variation persisted even after adjustment for patient characteristics. Multivariable analysis showed that the odds of being on warfarin decreased significantly with age and increasing comorbidity, in blacks, and among those with low income. Seeing a cardiologist (OR 1.10; 95% CI 1.05-1.16), having a PCP (OR 1.23; 95% CI 1.17-1.29), and CHADS(2) score of 2 or greater (OR 1.09; 95% CI 1.01-1.17) were associated with increased odds of warfarin use. CONCLUSIONS:Warfarin use rates vary by patient characteristics and region, with higher rates among residents of the Midwest and among patients seen by cardiologists and PCPs. Preventing stroke-related disability in AF requires implementation of evidence-based initiatives to increase warfarin use.
Authors: James V Freeman; Ruo P Zhu; Douglas K Owens; Alan M Garber; David W Hutton; Alan S Go; Paul J Wang; Mintu P Turakhia Journal: Ann Intern Med Date: 2010-11-01 Impact factor: 25.391
Authors: Yoko Miyasaka; Marion E Barnes; Bernard J Gersh; Stephen S Cha; Kent R Bailey; Walter P Abhayaratna; James B Seward; Teresa S M Tsang Journal: Circulation Date: 2006-07-03 Impact factor: 29.690
Authors: Brian F Gage; Elena Birman-Deych; Roger Kerzner; Martha J Radford; David S Nilasena; Michael W Rich Journal: Am J Med Date: 2005-06 Impact factor: 4.965
Authors: Andrew B Hughey; Xiaokui Gu; Brian Haymart; Eva Kline-Rogers; Steve Almany; Jay Kozlowski; Dennis Besley; Gregory D Krol; Syed Ahsan; Scott Kaatz; James B Froehlich; Geoffrey D Barnes Journal: J Thromb Thrombolysis Date: 2018-10 Impact factor: 2.300
Authors: Katie E Shean; Thomas F X O'Donnell; Sarah E Deery; Alexander B Pothof; Joseph R Schneider; Caron B Rockman; Brian W Nolan; Marc L Schermerhorn Journal: J Vasc Surg Date: 2018-03-20 Impact factor: 4.268
Authors: Scott A Chapman; Catherine A St Hill; Meg M Little; Michael T Swanoski; Shellina R Scheiner; Kenric B Ware; M Nawal Lutfiyya Journal: BMC Health Serv Res Date: 2017-02-11 Impact factor: 2.655
Authors: J'Neka S Claxton; Pamela L Lutsey; Richard F MacLehose; Lin Y Chen; Tené T Lewis; Alvaro Alonso Journal: J Stroke Cerebrovasc Dis Date: 2018-12-21 Impact factor: 2.136
Authors: Nianjun Liu; Marguerite R Irvin; Degui Zhi; Amit Patki; T Mark Beasley; Deborah A Nickerson; Charles E Hill; Jinbo Chen; Stephen E Kimmel; Nita A Limdi Journal: Pharmacogenomics Date: 2017-07-07 Impact factor: 2.533